Research Paper Volume 13, Issue 6 pp 8665—8687

MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling

Activation of the PI3K/AKT pathway impaired DDP sensitivity among GC cells. (A) Activation of the PI3K/AKT pathway does not affect expression of EMP1. (B) Use of PI3K/AKT activation impaired GC cells’ sensitivity toward DDP compared to the miR-95-3p inhibitor treated group. (C) Result from the BrdU assay further indicated that PI3K/AKT activator significantly enhanced DDP-resistant cell survival rate compared to the miR-95-3p inhibitor-treated group. (D) Results from flow cytometry demonstrated that PI3K/AKT activator could conspicuously decrease cellular apoptosis rate compared to the miR-95-3p inhibitor treated group. ***p

Figure 9. Activation of the PI3K/AKT pathway impaired DDP sensitivity among GC cells. (A) Activation of the PI3K/AKT pathway does not affect expression of EMP1. (B) Use of PI3K/AKT activation impaired GC cells’ sensitivity toward DDP compared to the miR-95-3p inhibitor treated group. (C) Result from the BrdU assay further indicated that PI3K/AKT activator significantly enhanced DDP-resistant cell survival rate compared to the miR-95-3p inhibitor-treated group. (D) Results from flow cytometry demonstrated that PI3K/AKT activator could conspicuously decrease cellular apoptosis rate compared to the miR-95-3p inhibitor treated group. ***p<0.001, **p<0.01.